SAN reveals baseball DIEGO--(Business Wire)--Ligand chicago cubs uncovers Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that asubsidiary of Ligand has entered into an exclusive license agreement withParinGenix Inc. under which ParinGenix was granted exclusive license rights tothree issued U.S. patents relating to certain desulfated heparin compounds.Under the terms of this agreement, Ligand will receive an upfront payment aswell as a royalty on net sales in the United States by ParinGenix of 2-O, 3-Odesulfated heparin products. ParinGenix`s lead compound, PGX-100 is anintravenous formulation of 2-O, 3-O desulfated heparin which is in a Phase IIbtrial for the treatment of acute COPD exacerbations. "We are pleased to enter into this collaboration, which monetizes intellectualproperty acquired in our 1995 merger with Glycomed. Furthermore, this deal addsanother potential lucrative royalty stream to Ligand`s already promising list ofpartnered, fully funded, royalty-bearing programs," said John L.
Higgins,President and Chief Executive Officer of Ligand Pharmaceuticals baseball managers . "The agreementwith ParinGenix further validates Ligand`s rich intellectual property portfolio,which has gained significant industry recognition, including Ligand being namedas a top innovator in the Patent Board`s Pharmaceuticals Patent Scorecard." Commenting on the transaction, Stephen G chicago cubs ringtones . Marcus M.D., President and ChiefExecutive Officer of ParinGenix stated, "We are pleased to have obtained anexclusive license to these three patents which expand and strengthen ourintellectual property portfolio chicago fire . Our lead compound, 2-O, 3-O desulfated heparin,has minimal anticoagulant activity while retaining the robust anti-inflammatoryand other biologic activities of unfractionated heparin." About Ligand PharmaceuticalsLigand discovers and develops new drugs that address critical unmet medicalneeds of patients with muscle wasting, frailty, hormone-related diseases,osteoporosis, inflammatory diseases, anemia, asthma, rheumatoid arthritis andpsoriasis cubbies . Ligand's proprietary drug discovery and development programs arebased on advanced cell-based assays, gene-expression tools, ultra-highthroughput screening and one of the world`s largest combinatorial chemicallibraries.
Ligand has strategic alliances with major pharmaceutical andbiotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon,GlaxoSmithKline, Schering-Plough, Pfizer and Wyeth Pharmaceuticals baseball ticket . With ninepharmaceutical deals and more than twenty different molecules in various stagesof development, Ligand utilizes proprietary technologies for identifying drugswith novel receptor and enzyme drug targets cubbies caps . About ParinGenixParinGenix Inc., is developing PGX-100, an intravenous formulation of 2-O, 3-Odesulfated heparin for the treatment of acute exacerbations of chronicobstructive pulmonary disease (COPD) and other inflammatory lung diseases cubbies hat . Aplacebo-controlled, randomized, double-blind, Phase IIb trial is ongoing insubjects with COPD exacerbations chicago cubs . Caution Regarding Forward-Looking StatementsThis news release contains forward looking statements by Ligand that involverisks and uncertainties and reflect Ligand`s judgment as of the date of thisrelease. Actual events or results may differ from Ligand`s expectations. Forexample, there can be no assurance that any product in the Ligand or ParinGenixpipelines will be successfully developed, that regulatory approvals will begranted, that patient and physician acceptance of these products will beachieved, that final results of human clinical trials will be consistent withany interim results or that final results will be supportive of regulatoryapprovals required to market products.
Additional information concerning theseand other risk factors affecting Ligand`s business can be found in prior pressreleases available via as well as in Ligand`s public periodicfilings with the Securities and Exchange Commission at Liganddisclaims any intent or obligation to update these forward-looking statementsbeyond the date of this release baseball tickets . This caution is made under the safe harborprovisions of the Private Securities Litigation Reform Act of 1995 Ligand Pharmaceuticals IncorporatedJohn L chicago cubs ringtones . Higgins, President and CEOErika Luib, Investor Relations858-550-7896orLippert/Heilshorn & AssociatesDon Markley, Copyright Business Wire 2009 chicago fire . FrontDoor`s Extensive Library of Home Sales Listings and Dynamic Home-relatedContent and Video Now Available on Local Media Web SitesKNOXVILLE, Tenn.--(Business Wire)--HGTV`s real estate Web site FrontDoor now opens the door for millions ofadditional Web users to find the latest in home listings combined with trustedhome-related videos and information . A new strategic content distributionpartnership announced today will see FrontDoor content featured prominentlyacross the Internet Broadcasting network of sites. ( http://) Launched in late 2007, FrontDoor has rapidly risen to become a leader in realestate Web services thanks to the demonstrated leadership and expertise of HGTV-- seen in more than 95 million U.S households and the No. 1 media resource forhome and garden content -- combined with a rich, video- and image-centricexperience offering the best and latest in listings and real estate relatedinformation.
Comments are closed.